Gerilimzumab - argenx

Drug Profile

Gerilimzumab - argenx

Alternative Names: ARGX 109; GB 224; RYI 008

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator arGEN-X
  • Developer argenx; Bird Rock Bio; Genor Biopharma
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-6 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • No development reported Autoimmune disorders; Cancer; Ovarian cancer; Renal cell carcinoma

Most Recent Events

  • 01 Nov 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (SC) (ChiCTR-IIR17013205)
  • 03 Jan 2017 ANVISA and CONEP grant approval for conducting a phase II trial for Rheumatoid arthritis in Brazil
  • 24 Dec 2016 Genor Biopharma received a clinical trial approval from China Food and Drug Administration for gerilimzumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top